2024 Here we go again., page-276

Here’s a NASDAQ listed biotech company that took 20 years in the listed arena to get to its current state of being chased by multiple suitors, including Novartis. It is something that should not be lost on anyone, that the positive P3 readout for their main product came out only late last year, and the results for the P3 for 2 other products are not expected until mid 2025 and one year later.

https://www.genengnews.com/topics/drug-discovery/stockwatch-ma-talk-fuels-cytokinetics-stock-roller-coaster/#:~:text=Amgen%2C%20AstraZeneca%2C%20Johnson%20%26%20Johnson,healthcare%20equity%20research%20with%20B.

Here we have a local minnow which listed on the ASX in 2004 (unfortunately Australia does not have a separate board for techs and biotechs). Of course, on NASDAQ as well. However, looking at the next 18 months, the unexpectedly near term potential thrown up by the recent HF LVAD meeting with the FDA and an expected pre-BLA meeting to be scheduled really does compare extremely well, especially when it is happening at the same time as the adult aGVHD trial which should not take long to complete. (The latter might be preceded by an AA for kids’ SR-aGVHD, who knows.)

https://www.***.com/technology/what-investors-can-learn-from-analysing-r-and-d-spending-20240204-p5f2a9

I have a feeling that the company’s problem this and next year might become one of keeping interested partners and suitors at bay, for a change.